Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-09-06 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
北京市君泽君律师事务所关于特一药业非公开发行股票会后事项的承诺函
Regulatory Filings Classification · 95% confidence The document is a legal commitment letter from a law firm regarding post-issuance matters of a non-public stock offering by a company. It references regulatory approvals, audit reports, and compliance with securities laws, but does not contain financial statements or detailed financial analysis itself. The document is relatively short (2400 characters) and serves as a formal attestation and update on compliance and post-issuance conditions rather than a full financial report or announcement of financial results. It fits the category of a regulatory filing related to compliance and legal assurances rather than a financial report or announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-09-06 Chinese
东莞证券关于特一药业非公开发行股票会后事项的承诺函
Regulatory Filings Classification · 95% confidence The document is a commitment letter from Dongguan Securities Co., Ltd. regarding post-issuance matters of a non-public stock issuance by Te Yi Pharmaceutical Group Co., Ltd. It references regulatory approvals, audit reports, and compliance with securities laws and regulations. The document is a formal attestation and commitment letter related to the non-public issuance process, confirming no adverse events or changes affecting the issuance. It does not contain financial statements or detailed financial data itself but rather assurances and compliance confirmations. The document length is 2165 characters, which is relatively short and consistent with a letter or announcement rather than a full report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory submission and attestation letter related to the issuance but not a full financial report or announcement of voting results, capital changes, or other specific categories.
2021-09-06 Chinese
特一药业关于非公开发行股票会后事项的承诺函
Regulatory Filings Classification · 95% confidence The document is a commitment letter from 特一药业集团股份有限公司 regarding post-issuance matters of a non-public stock issuance. It references regulatory approvals, audit reports, and compliance with securities regulations. The document is relatively short (2001 characters) and primarily serves as a formal attestation or declaration about the status and compliance of the company post-issuance. It does not contain detailed financial statements or substantive financial data itself, but rather confirms the absence of adverse events or changes since the issuance. This fits the profile of a Regulatory Filing (RNS) rather than a full financial report or announcement of a report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-09-06 Chinese
关于非公开发行股票会后事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding post-issuance matters of a non-public stock issuance by 特一药业集团股份有限公司. It references regulatory approvals from the China Securities Regulatory Commission and mentions related commitment letters and audit reports available on a public information website. The document does not contain detailed financial statements or substantive financial data itself but rather discusses compliance and post-issuance regulatory filings. The length is short (995 characters), and it serves as a formal announcement of post-issuance matters rather than the issuance report or financial report itself. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2021-09-06 Chinese
大信会计师事务所关于特一药业非公开发行股票会后事项审核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by a certified public accounting firm regarding the post-issuance matters of a company's non-public stock issuance. It references specific audit standards and regulatory notices from the China Securities Regulatory Commission related to post-issuance supervision. The document includes an audit opinion on the company's post-issuance significant matters, confirming no material misstatements or adverse events affecting the issuance. It is not a full annual report or financial statement but a standalone audit report focused on a specific regulatory compliance area. The document length is 2661 characters, which is relatively short but contains substantive audit content rather than just an announcement. Therefore, it fits the category of an Audit Report / Information (AR). FY 2020
2021-09-06 Chinese
关于提前归还部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the early repayment of part of the temporarily supplemented working capital from raised funds. It discusses the use and repayment of idle raised funds for working capital purposes, including specific amounts and dates. There is no financial statement, detailed financial analysis, or comprehensive report content. The document is relatively short (872 characters) and serves as a formal notification of a financing activity related to capital management. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-09-02 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.